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Neutrophil extracellular traps and the
dysfunctional innate immune response of
cystic fibrosis lung disease: a review
Sheonagh M. Law* and Robert D. Gray
Abstract
Background: Cystic Fibrosis (CF) is a devastating genetic disease characterised primarily by unrelenting lung
inflammation and infection resulting in premature death and significant morbidity. Neutrophil Extracellular Traps
(NETs) are possibly key to inflammation in the disease. This review aims to draw together existing research
investigating NETs in the context of a dysfunctional innate immune system in CF.
Main body: NETs have a limited anti-microbial role in CF and studies have shown they are present in higher numbers
in CF airways and their protein constituents correlate with lung function decline. Innate immune system cells express
CFTR and myeloid-specific CFTR KO mice have greater neutrophil recruitment and higher pro-inflammatory cytokine
production to both sterile and bacterial inflammatory challenges. CFTR KO neutrophils have impaired anti-microbial
capacity and intrinsic abnormalities in the pH of their cytoplasm, abnormal protein trafficking, increased neutrophil
elastase and myeloperoxidase function, and decreased hypochlorite concentrations in their phagolysosomes.
Furthermore, neutrophils from CF patients have less intrinsic apoptosis and may be therefore more likely to make NETs.
CFTR KO macrophages have high intraphagolysosomal pH and increased toll-like receptor 4 on their cell surface
membranes, which inhibit their anti-microbial capacity and render them hyper-responsive to inflammatory stimuli,
respectively. Pharmacological treatments for CF target these intrinsic abnormalities of immune dysfunction. Emerging
evidence suggests that the absence of CFTR from neutrophils affects NETosis and the interaction of NETs with
macrophages.
Conclusion: Current evidence suggests that NETs contribute to inflammation and lung destruction rather than
working effectively in their anti-microbial capacity. Further studies focussing on the pro-inflammatory nature
of NET constituents are required to identify the exact mechanistic role of NETs in CF and potential
therapeutic interventions.
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Background
Cystic Fibrosis (CF) is an autosomal recessive disorder
caused by mutations in the CF transmembrane conduct-
ance regulator (CFTR) gene, which encodes a transmem-
brane anion channel transporting chloride and bicarbonate.
CF may give rise to the clinical manifestations of chronic
airway inflammation and infection, pancreatic insufficiency
causing malnutrition and diabetes mellitus, gastrointestinal
disease, and male infertility.
Presently around 11,000 people in the UK suffer from
CF and the median age of death is only 28 [1], with one
third of patients dying whilst waiting for a lung trans-
plant as morbidity and mortality principally relate to
chronic airway infection and inflammation [2]. A dys-
functional innate immune response is key to the lung
destruction seen. In some ways, CF can be compared to
an autoimmune disease in which the exogenous antigen
is identified as pathogens in the airways. It has been
known for over 40 years that CF patients have high
levels of DNA in their airways, of which Neutrophil
Extracellular Traps (NETs) have recently emerged as the
principal source [3, 4].
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Here we aim to review the role of NETs in CF lung
disease in the context of a dysfunctional innate immune
system and discuss the importance of better understand-
ing the cellular interactions, in order to find new anti-
inflammatory therapies for CF patients.
Main body
The anti-microbial capacity of neutrophils is impaired in
the context of CFTR dysfunction
CF lung disease is characterised by a neutrophil-dominant
inflammation, with neutrophils accounting for 80% of the
total cells present in CF sputum, even when patients are clin-
ically stable [5]. Although uncommon, CF provides a strong
model with which to investigate the pro-inflammatory po-
tential of NETs, which may also be informative of other
neutrophil-dominated diseases such as Chronic Obstructive
Lung disease, non-CF Bronchiectasis and Pneumonia. Neu-
trophils employ a number of antimicrobial strategies such as
phagocytosis, the generation of Reactive Oxygen Species
(ROS), degranulation, and NET formation, all of which have
been described as abnormal in CF [6–9].
CFTR −/− neutrophils have impaired transport of chlor-
ide into the phagolysosome from the cytoplasm and
accordingly have increased cytosolic concentrations of
Na+ and Cl− and reduced Cl- concentrations in their
phagolysosome [7]. This leads to impaired destruction of
pathogens because chloride, alongside hydrogen peroxide,
is the substrate for hypochlorite, a potent ROS found
within the phagolysosome and responsible for microbial
digestion [10]. The abnormal pH of CFTR −/− neutrophils’
cytoplasm leads to excessive degranulation of azurophilic
granules, thus increasing the release of anti-microbial en-
zymes such as peroxidases (e.g. myeloperoxidase, MPO),
proteases (e.g. neutrophil elastase, NE) and anti-microbial
peptides [11]. If there are high extracellular levels of NE, it
overwhelms the binding capacity of the anti-protease α1-
antitrypsin [12], and degradation of elastin within lung
parenchyma contributes to lung destruction and bronchi-
ectasis seen in CF [13]. The abnormal cytosolic ion con-
centrations also cause inactivation of Rab27a – a protein
crucial to granule trafficking – and in turn, defective de-
granulation and bacterial killing [8]. Pohl et al. demon-
strated that this defect was corrected by treatment of
G551D CF patients with Ivacaftor (an ion channel potenti-
ator) [8].
We have recently shown that CFTR −/− neutrophils
have a primary defect causing decreased spontaneous
apoptosis and increased levels of NET formation that
can promote inflammation through their interactions
with macrophages [9]. This defect in apoptosis leading
to increased neutrophil survival in CF has been de-
scribed by other authors [14, 15] and may be detrimental
to the host due to defective resolution of infectious or
inflammatory insults.
Neutrophil extracellular traps
NET formation, or “NETosis”, may be the favoured
cell death process by CFTR −/− neutrophils, over
apoptosis. NETosis can be triggered by neutrophils
undergoing oxidative burst [16] leading to enzyme-
mediated decondensation of nuclear chromatin,
rupture of the nuclear membrane and release of chro-
matin and cellular proteins into the extracellular
space. NETs form web-like structures composed of
de-condensed Deoxyribonucleic acid (DNA), citrulli-
nated histones and several pro-inflammatory cytosolic
and granule proteins including calprotectin, NE, MPO
and LL37 [17, 18]. A spatial relationship between
DNA and these proteins is a key requirement to dif-
ferentiate NETs from fibrin or bacterial DNA in vitro
[18]. Figure 1 below shows an immunofluorescence
image of NETs in vitro.
NETs may be a key source of inflammation in CF lung
disease
NETs were initially described in 2004 as an anti-
bacterial defence mechanism [19] but their potential
as a driver of inflammation in CF has yet to be inves-
tigated and may provide a therapeutic target in lung
disease. In particular, the interaction of NETs with
other immune cells and lung epithelial cells may be
of key importance. Throughout this review, we will
consider NETs in the context of the dysfunctional in-
nate immune system in CF, which is characterised by
frustrated inflammation.
Original studies demonstrated that NETosis was a
form of cell death distinct from apoptosis, potentially
utilised as a last resort in neutrophils’ anti-microbial de-
fence strategies. However other evidence has suggested
that neutrophils may also release NETS in vivo without
Fig. 1 Overlay of immunofluorescence images demonstrating
co-localisation of DNA and myeloperoxidase (MPO) on in vitro NETs
stained with Hoechst antibody (blue, binds DNA) and anti-MPO
antibody (green)
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cell death in a process termed “vital” NETosis [20].
Furthermore, vital NETosis can occur by release of mito-
chondrial DNA [21], which does not require the pres-
ence of citrullinated histones on the DNA backbone [9].
Whether NETosis with cell death and vital NETosis rep-
resent the same or different biological phenomena re-
mains unclear at present [19, 22].
NETosis is triggered by microbial (bacterial, fungal
and viral), inflammatory (e.g. IL-8, IFN-ɣ, TNF-α), and
endogenous “sterile” triggers (e.g. nitric oxide, platelets,
complement, monosodium urate crystals) [23]. An ele-
gant summary of the molecular mechanisms regulating
NETosis is described in the recent review by Papayanno-
poulos [24]. Figure 2 shows the intracellular pathways
understood to be involved in NETosis, although Kenny
et al. recently demonstrated that NETosis can occur
through numerous signalling mechanisms, dependent
upon the stimulant to which neutrophils were exposed
[25] (Fig. 3).
NETs have a limited anti-microbial role in CF
NETs have been conserved throughout evolution for
their anti-microbial role. Indeed extracellular trap for-
mation has been demonstrated as critical for encapsula-
tion of microbes by haemocytes of the shore crab
Carcinus maenas [27], and NETs (or equivalent) have
been described in fish [28], chickens [29], dogs [30] and
pigs [31]. Studies in humans have also demonstrated
NETs to be anti-microbial [20]. Whilst laboratory strains
and CF clinical isolates of Pseudomonas Aeruginosa
(P.Aeruginosa) strongly trigger NET release [32], late iso-
lates within CF airways acquire resistance against NETs
[33, 34]. Furthermore, Fuchs et al. showed that only 25%
of neutrophils form NETs to kill S. Aureus in vitro; the
majority of bacterial killing was by phagocytosis [16].
NETosis appears better-suited to tackling large mi-
crobes, such as fungal hyphae, which are too large to be
phagocytosed [35]. Marcos et al. found NETs in airway
samples of CF patients were associated with fungal col-
onisation with Aspergillus Fumigatus (A. Fumigatus) but
not with bacterial infection [4].
We hypothesise that in the context of CF, NETs could play
only a minor anti-microbial role, as despite the presence of
large numbers of activated neutrophils and extracellular
DNA, patients suffer recurrent lower respiratory tract infec-
tions and colonisation with organisms such as Staphylococ-
cus Aureus (S. Aureus), P. Aeruginosa and A. Fumigatus as
the host’s defence mechanisms are overwhelmed.
NETs can be thought of as the Jekyll and Hyde of im-
munity; on one hand, they fulfil their bacteriostatic and
bactericidal roles in lower order species beautifully [25]
but on the other hand, due to the presence of an adap-
tive innate immune system, function as detrimental
auto-antigens in human autoimmune disease.
Fig. 2 Neutrophil Extracellular Trap (NET) production by a neutrophil. Neutrophils are stimulated to form NETs by several microbial, inflammatory
and sterile endogenous triggers. These bind onto cell surface receptors including Toll-like Receptor 4, cytokine and complement receptors.
Receptor binding leads to increased calcium release from the endoplasmic reticululm, activating Protein Kinase C (PKC). This leads to activation
of NADPH Oxidase on the cell membrane and lysosomes, forming superoxide which reacts with water and chloride to form hypochlorite.
Hypochlorite activates Protein Arginine Deiminase 4 (PAD4) which translocates to the nucleus where it catalyses hypercitrullination of histones 3
and 4 [26]. This causes the histones to lose their positive charge and in doing so weakens their binding to DNA, leading to decondensation of
chromatin. There is loss of plasma membrane integrity then decondensed chromatin and histones are expelled into the extracellular space where
they form complexes with granule/cytosolic proteins such as myeloperoxidase, neutrophil elastase and calprotectin. Recent research suggests NET
production is an end-point of numerous cell signalling pathways – not all of which require each of the above steps – dependent upon the
stimulant used to induce NETosis [25].
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NETs contribute to autoimmune disease and sterile
inflammation
There are a number of diseases characterised by NET-
mediated sterile inflammation including Systemic Lupus
Erythematosus (SLE), psoriasis, small vessel vasculitis,
rheumatoid arthritis, gout, venous thrombosis and car-
diovascular disease [23, 36–39]. The autoantibodies used
by clinicians to diagnose some of these conditions e.g. anti-
MPO, anti-Proteinase 3, extractable nuclear antibodies, anti-
nuclear antibodies and anti-dsDNA antibodies – all target
NET-bound proteins. SLE patients unable to clear NETs suffer
renal impairment secondary to lupus nephritis [36]. Addition-
ally, during the pathophysiology of atherosclerosis, NETs acti-
vate macrophages to release pro-inflammatory cytokines
which in turn activate T helper 17 cells, driving further im-
mune cell recruitment and exacerbating inflammation [39].
It follows that NETs may be an important pro-
inflammatory component in the CF airway, where in-
flammation is driven by chronic infection.
The pathophysiological role of NETs in CF
Higher levels of free DNA are present in bronchoalveolar
lavage (BAL) samples of CF patients compared to healthy
controls [40]. Originally it was thought this DNA was de-
rived from apoptotic and necrotic cell debris but recent
studies have suggested most arises from NETs [3, 4].
NETosis can be triggered by P. Aeruginosa [41], a major
pathogen in CF lung disease, and several studies have
demonstrated that NETs are found in higher levels in air-
way samples from CF patients compared to healthy con-
trols and are associated with poorer lung function [3, 4].
DNase is a treatment used mainly in adult CF patients
and we hypothesise it targets NETs. It is a nebulised ther-
apy used to improve patients’ lung function and reduce
exacerbation rate in both paediatric and adult patients
[42–44]. It functions to cleave the excessive extracellular
DNA to decrease sputum viscosity [45] but also reduces
airway inflammation [46].
This DNA backbone of NETs is the scaffolding upon
which several pro-inflammatory proteins reside. These
have been implicated in the pathophysiology of lung in-
jury and inflammation and key proteins shall now be
discussed in turn.
Histones
Histones, for example, are known to cause lung injury in
mice [47–50] in part through charge-mediated binding
and disruption of phosphodiester bonds within cell
membranes, thus causing toxic calcium influx [47] and
through TLR2 and TLR4 binding [49]. Histone sub-types
- H1, H2A, H2B, H3 - have defined effects upon murine
and human phagocytes; they can lead to cell swelling,
lactate dehydrogenase release, cytokine and chemokine
release to varying degrees [49]. The treatment of mice
with DNase has been shown to reduce citrullinated H3
levels in BAL fluid and protect from Lipopolysaccharide
(LPS)-induced acute lung injury [50].
Neutrophil Elastase (NE)
NE is another key NET constituent implicated in the
pathophysiology of CF. It is an azurophilic granule protein
functioning to degrade phagocytosed proteins. Within the
Fig. 3 Several mechanisms require investigation concerning the dysfunctional innate immune response and NETs in Cystic Fibrosis (CF). It may
be that CFTR −/− neutrophils are hyper-stimulatory to macrophages due to increased NET production and CFTR −/− alveolar macrophages produce higher
levels of pro-inflammatory cytokines, driving chemotaxis of more neutrophils in a self-perpetuating cycle of inflammation. Co-culture experiments with
airway epithelial cells, NETs and macrophages would mimic in vivo conditions. Targeting this cycle, e.g. by reducing NET production, inhibiting
NET-protein’s deleterious functions or promoting NET clearance would provide new targets for the treatment of CF
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airways, NE degrades protein structures including elastin
and collagen [6]. It is found in high concentrations in CF
sputum and BAL samples and levels correlate with lung
function decline in CF [13, 51]. Dubois and co-workers
demonstrated that in vitro DNase treatment significantly
increased NE activity [52]. They concluded that negatively
charged DNA binds to anionic NE and in doing so pro-
tects it from proteolytic degradation by anti-proteases in
the lungs. This interaction likely contributes to the
protease-anti-protease imbalance seen in CF lung disease,
which leads to parenchymal destruction.
Calprotectin
Calprotectin, a neutrophil cytosolic protein, is also in-
corporated onto NETs during NETosis and has
received renewed interest in the field of CF. We have
demonstrated that Calprotectin could be used as a
biomarker for CF. Both sputum and serum calprotec-
tin levels significantly decrease following treatment of
an exacerbation, and serum calprotectin levels were
negatively correlated with Forced Expiratory Volume
in one second (a measure of patient lung function)
and predicted time to next exacerbation [53].
Calprotectin also promotes inflammation by function-
ing as an alarmin [54]. Calprotectin on NETs has
been shown to be crucial as an anti-fungal defence in
mice [55] but the potential for NET-bound calprotec-
tin to promote inflammation is yet to be investigated.
Bactericidal permeability-increasing protein (BPI)
BPI is an antimicrobial peptide, which targets gram-
negative bacteria and is stored in azurophilic granules of
neutrophils. It becomes localised onto NETs following
PMA-induced NET formation [56]. CF patients develop
anti-BPI autoantibodies, levels of which negatively
correlate with lung function [56]. This gives further evi-
dence that NETs are involved in autoimmunity in CF.
Some of these pro-inflammatory proteins have been
visualised using the recently developed intra-vital mi-
croscopy, whereby biological cellular processes are im-
aged in living animals, a technique revolutionising the
study of immunology [57]. Kolaczkowska et al. used
intra-vital microscopy to image Methicillin-resistant S.
Aureus (MRSA)-induced NETs and their associated NE
and MPO within the liver sinusoids of mice [58]. They
demonstrated that blocking NET formation protected
the liver from MRSA-induced damage, suggesting
NETs, not bacteria, were responsible for the damage
observed [53].
Given that the above proteins found upon NETs
correlate with lung function decline in CF and cause in-
flammation, it is possible that NETS are involved in the
pathophysiology of CF, although mechanisms require
further elucidation. We hypothesise lack of CFTR causes
abnormal function of innate immune system cells lead-
ing to excessive production and/or impaired clearance of
NETs. Additionally, we have recently shown that CF
neutrophils live longer due to decreased apoptosis and
produce more NETs compared to healthy controls [9],
although the underlying mechanisms require further
investigation.
Neutrophils express CFTR and are dysfunctional in CF
A simple explanation for the abnormal accumulation of
NETs in CF in might be that there are higher numbers of
neutrophils within the airways. Alternatively, CFTR −/− neu-
trophils may produce excessive amounts of NETs via ab-
normal intracellular pathways. Painter et al. used reverse
transcriptase-polymerase chain reaction, immunofluores-
cence staining, and immunoblotting to demonstrate low
level expression of CFTR in neutrophils at both mRNA and
protein levels, with CFTR present in secretory vesicles and
phagolysosomes [7], suggesting it could have a number of
roles in neutrophil function. Bonfield et al. bred whole-
body and myeloid-specific CFTR inactivated mice and chal-
lenged them with P. Aeruginosa lung infection: CFTR −/−
mice had increased neutrophil numbers, IL-1β and IL-6 in
BAL at day 10 post-infection [59]. The same was seen for
myeloid cell CFTR −/− mice, albeit to a lesser extent [59].
Su et al. demonstrated that a lack of functional CFTR in
neutrophils (either by pharmacological inhibition or knock-
out chimera model) promoted LPS-induced lung inflam-
mation and injury in mice [60]. Taken together, these three
studies support the view that dysfunctional neutrophil
CFTR contributes to lung inflammation in CF, although do
not implicate NETs directly.
Evidence is sparse with regard to intrinsic abnormal-
ities in NETosis in CFTR −/− neutrophils. One study spe-
cifically addressing defects in NETosis was that by
Akong-Moore et al., who performed in vitro experi-
ments stimulating neutrophils to form NETs using PMA
in the presence and absence of chloride in the culture
media. They found NETosis was significantly decreased
in the absence of extracellular chloride [61], which may
be key in CF.
Intrinsic abnormalities of CF macrophages may contribute
to accumulation of NETs in CF airways
Clearance of NETs from the airways is dependent upon
several factors including mucociliary clearance, DNase
activity and phagocytosis by macrophages, which phago-
cytose NETs then digest them within lysosomes, a
process facilitated by pre-degradation by DNase and one
which does not result in pro-inflammatory cytokine se-
cretion [62]. This process may be deficient in CF given
that CFTR-deficient or CFTR −/− macrophages have ab-
normally high intraphagolysosomal pH, which was
shown to impair bactericidal activity [63].
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Furthermore, Bruscia et al. have shown that CFTR −/−
macrophages have significantly higher levels of Toll-like
Receptor 4 (TLR 4) on plasma cell membranes com-
pared to wild-type macrophages [64]. TLR 4 is a pro-
tein that recognises pathogen-associated molecular
patterns such as that from LPS, found on the cell
membranes of Gram-negative bacteria. They found
that in response to LPS challenge, CF macrophages
produced significantly higher amounts of the pro-
inflammatory cytokines TNF-α, IL-6 and GMCSF,
demonstrating CF macrophages have a hyper-
responsive phenotype [64]. This may be via the NFκB
and mitogen-activated protein kinases (MAPK) cell
signalling pathways, which increase gene transcription
of pro-inflammatory cytokines, including IL-8 [64,
65], a potent chemoattractant for neutrophils. Inter-
estingly, CFTR has recently been shown to prevent
macrophage-driven inflammation and atherogenesis in
apolipoprotein E-deficient mice, via inhibition of NFκB
and MAPK activation [66]. To conclude, intrinsic abnor-
malities of CF macrophages contribute to the chronic
neutrophilic inflammation seen in CF lung disease due to
their hyper-responsive phenotype to inflammatory stimuli.
Pharmacological treatments for CF target these intrinsic
abnormalities of immune dysfunction
Aforementioned macrophage and neutrophil dysfunctions
are the target of treatments given to CF patients. For
example, the macrolide antibiotic Azithromycin functions
in an immunomodulatory capacity to reduce pro-
inflammatory cytokine production from alveolar macro-
phages and is known to reduce pulmonary exacerbation
rates and promote weight gain in CF [67, 68]. Ivacaftor, a
CFTR potentiator, corrects neutrophil Rab27a trafficking
and normalises cytosolic Na+ and Cl− concentration ab-
normalities in vitro [8]. The decreased apoptosis we dem-
onstrated in CF neutrophils was reversed by Ivacaftor in
patients with gating (G551D) mutations [9].
Cyclin-dependent kinase (CDK) proteins are involved
in cell cycle control and are now believed to play a role
in immunity; CDK 4 and 6 have recently been shown to
regulate NET formation [69]. (R)-Roscovitine, a CDK in-
hibitor, is a drug currently under investigation in the
field of CF. It has been shown to: 1) restore normal pH
within phagolysosomes of CF alveolar macrophages; 2)
induce neutrophil apoptosis, which is impaired in CF
neutrophils; and 3) act as a CFTR modulator by redu-
cing DF508-CFTR degradation and aiding its transfer to
the plasma membrane [70]. Interestingly, the phase II
study entitled “Evaluation of (R)-Roscovitine Safety and
Effects in Subjects With Cystic Fibrosis, Homozygous
for the F508del-CFTR Mutation (ROSCO-CF)” is
ongoing to assess the safety of increasing doses of (R)-
Roscovitine in adult CF subjects chronically infected
with Pseudomonas aeruginosa [71]. Whilst not specific-
ally targeting NETs, this drug represent a future pharma-
cological treatment for CF patients.
This review has presented a strong argument for
dysfunctional host innate immune responses contrib-
uting to lung injury in CF. What remains uncertain
is the interplay between NETs and macrophages in
CF – NETs may be hyper-stimulatory and macro-
phages hyper-responsive.
Suggestions for future work
This literature review has identified gaps in our know-
ledge regarding the interplay between NETs and innate
immune system cells, which contributes to the patho-
physiology of CF. Whether the higher levels of NETs in
CF airways samples is the result of over-production by
the CFTR−/− neutrophil, increased survival of CFTR−/−
neutrophils or reduced clearance by alveolar macro-
phages, requires investigation. We do not know the cell
signalling pathways causing CFTR−/− neutrophils to have
prolonged survival. There is a paucity of data on how
absence of CFTR affects NETosis pathways. From a clin-
ical perspective, it may be that DNase should be intro-
duced as a therapeutic agent earlier in disease than
present practice, thus reducing inflammation caused by
the dysfunctional immune system, even before chronic
infection is established.
Conclusions
CF is a devastating genetic disease resulting in premature
death of patients, usually because of respiratory failure. The
dysfunctional innate immune response, specifically the
interplay between neutrophils and macrophages, may have
an important role in the pathophysiology of CF lung dis-
ease. We hypothesise NETs are a hindrance rather than a
help in CF, contributing to inflammation and lung damage
rather than working effectively in their anti-microbial cap-
acity. Further studies are essential to investigate the pro-
inflammatory nature of NET constituents with the aim of
identifying precise, new treatment strategies for CF.
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